Ep. Toy et al., The activated macrophage colony-stimulating factor (CSF-1) receptor as a predictor of poor outcome in advanced epithelial ovarian carcinoma, GYNECOL ONC, 80(2), 2001, pp. 194-200
Objective. We have previously shown that the macrophage colony-stimulating
factor receptor (CSF-1R) and its ligand, CSF-1, together predict poor progn
osis in epithelial ovarian carcinoma. The activated or phosphorylated form
of CSF-1R (CSF-1Rphos) has been associated with enhanced invasive and metas
tatic potential. Our goal is to correlate CSF-1Rphos with known prognostic
factors and to determine its role in predicting outcome in advanced ovarian
cancer.
Methods. One hundred forty-two primary and forty-seven metastatic epithelia
l ovarian tumors from 98 patients were immunohistochemically stained using
antibodies PY809 and PY723 against their respective tyrosine residues assoc
iated with local invasiveness and metastasis. chi (2) analysis was used to
correlate CSF-1Rphos staining and previously studied prognosticators within
each group. Kaplan-Meier curves of survival were compared using the log-ra
nk test with significance of P < 0.05.
Results. Forty-seven and nine-tenths percent (68/142) of primary tumors and
forty-eight and nine-tenths percent (23/47) of metastatic tumors stained p
ositive for PY809 and PY723, respectively. The PY809+ group was strongly as
sociated with CSF-1R (P = 0.015) as was the PY723 + group (P = 0.025) in it
s respective subset. CSF-1Rphos by itself was not a predictor of survival o
r disease-free interval (DFI) in either the primary or metastatic group. Ho
wever, when combined with CSF-1R in the metastatic group, the two together
predicted worse survival (P = 0.007) and decreased DFI (P = 0.011).
Conclusions, Phosphorylated tyrosine kinase receptors are detectable in a s
ignificant number of ovarian tumors, Staining strongly correlates with CSF-
1R. PY723+ metastases coexpressing CSF-1R portend a highly significant decr
ease in survival and increased risk of recurrence which may serve to identi
fy high-risk ovarian cancer patients. (C) 2001 Academic Press.